臨床眼科67巻3号

2013年03月発行

特集 第66回日本臨床眼科学会講演集（1） 原著

ラニビズマブ単独治療の導入期に連続3回投与は必要か

著者： 井尻茂之¹ 杉山和久¹

所属機関： ¹金沢大学医薬保健学域医学系視覚科学

ページ範囲：P.291 - P.296

要約　目的：滲出型加齢黄斑変性に対するラニビズマブ導入期連続3回投与の必要性についての検討。対象と方法：導入期途中でdry macula（網膜浮腫および網膜下液の両者を認めない状態）を得たため1回または連続2回で終了した31眼（2回以下群）と，導入期途中でdry maculaを得たが連続3回投与した14眼（3回群）の治療成績を後ろ向きに比較した。結果：中心窩網膜厚と視力の改善量は，1か月，2か月，3か月，6か月，12か月時において2群間で有意差がなかった。12か月間の投与回数は，2回以下群のほうが有意に少なかった。結論：導入期途中でdry maculaが得られれば，連続3回投与する必要性はない可能性がある。

参考文献

1）Brown DM, Michels M, Kaiser PK et al：ANCHOR Study Group：Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration：Two-year results of the ANCHOR study. Ophthalmology　116：57-65, 2009

2）Rosenfelt PJ, Brown DM, Heier JS et al：MARINA Study Group：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med　355：1419-1431, 2006

3）Tano Y, Ohji M：EXTEND-I Study Group：EXTEND-I：safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol　88：309-316, 2010

4）Tano Y, Ohji M：EXTEND-I Study Group：Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I Study Group. Acta Ophthalmol　89：208-217, 2011

5）Gupta B, Adewoyin T, Patel SK et al：Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol　95：386-390, 2011

6）Ikemori S, Kato A, Yasukawa T et al：Effect of a single-dose of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration. J Clin Exp Ophthalmol　3：221. doi：10.4172/2155-9570.1000221, 2012

7）CATT Research Group, Martin DF, Maguire MG, Ying GS et al：Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med　364：1897-1908, 2011

8）Fung AE, Lalwani GA, Rosenfeld PJ et al：An optical coherence tomography-guided variable-dosing regimen with intravitreal ranibizumab（Lucentis）for neovascular age-related macular degeneration. Am J Ophthalmol　143：566-583, 2007

9）田野保雄・大路正人・石橋達朗・他：ラニビズマブ治療指針策定委員会：ラニビズマブ（遺伝子組換え）の維持期おける再投与ガイドライン．日眼会誌　113：1098-1103，2009

10）Koizumi H, Yamagishi T, Yamazaki T et al：Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol　95：1555-1559, 2011

11）Arosa S, Mckibbin M：One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye　25：1034-1038, 2011

12）Cho M, Barbazetto IA, Freund KB：Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol　148：70-78, 2009

13）Rothenbuehler SP, Waeber D, Brinkmann CK et al：Effect of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol　147：831-837, 2009

14）Querques G, Azrya S, Martinelli D et al：Ranibizumab for exudative age-related macular degeneration：24-month outcomes from a single-centre institutional setting. Br J Ophthalmol　94：292-296, 2010

15）Carneiro AM, Mendonça LS, Falcão MS et al：Comparative study of 1＋PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol　6：1149-1157, 2012

16）Mitchell P, Korobelnik JF, Lanzetta P et al：Ranibizumab（Lucentis）in neovascular age-related macular degeneration：evidence from clinical trials. Br J Ophthalmol　94：2-13. 2010

17）Schmidt-Erfurth U, Eldem B, Guymer R et al：EXCITE Study Group：Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration：the EXCITE study. Ophthalmology　118：831-839, 2011